Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Pouysségur J[au]:

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Brand A et al. Cell Metab. (2016)

Hypoxia and cellular metabolism in tumour pathophysiology. Parks SK et al. J Physiol. (2017)

ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy? Buscà R et al. Front Cell Dev Biol. (2016)

Search results

Items: 1 to 50 of 414

1.

Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages.

Bohn T, Rapp S, Luther N, Klein M, Bruehl TJ, Kojima N, Aranda Lopez P, Hahlbrock J, Muth S, Endo S, Pektor S, Brand A, Renner K, Popp V, Gerlach K, Vogel D, Lueckel C, Arnold-Schild D, Pouyssegur J, Kreutz M, Huber M, Koenig J, Weigmann B, Probst HC, von Stebut E, Becker C, Schild H, Schmitt E, Bopp T.

Nat Immunol. 2018 Nov 5. doi: 10.1038/s41590-018-0226-8. [Epub ahead of print]

PMID:
30397348
2.

Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolism.

Ždralević M, Brand A, Di Ianni L, Dettmer K, Reinders J, Singer K, Peter K, Schnell A, Bruss C, Decking SM, Koehl G, Felipe-Abrio B, Durivault J, Bayer P, Evangelista M, O'Brien T, Oefner PJ, Renner K, Pouysségur J, Kreutz M.

J Biol Chem. 2018 Oct 12;293(41):15947-15961. doi: 10.1074/jbc.RA118.004180. Epub 2018 Aug 29.

PMID:
30158244
3.

AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.

Brolih S, Parks SK, Vial V, Durivault J, Mostosi L, Pouysségur J, Pagès G, Picco V.

BMC Cancer. 2018 Mar 5;18(1):249. doi: 10.1186/s12885-018-4169-0.

4.

The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.

Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pages G, Burel-Vandenbos F, Mazure NM.

PLoS One. 2018 Feb 26;13(2):e0193477. doi: 10.1371/journal.pone.0193477. eCollection 2018.

5.

Metabolic Plasiticy in Cancers-Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs.

Ždralević M, Marchiq I, de Padua MMC, Parks SK, Pouysségur J.

Front Oncol. 2017 Dec 20;7:313. doi: 10.3389/fonc.2017.00313. eCollection 2017. Review.

6.

The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).

Cormerais Y, Massard PA, Vucetic M, Giuliano S, Tambutté E, Durivault J, Vial V, Endou H, Wempe MF, Parks SK, Pouyssegur J.

J Biol Chem. 2018 Feb 23;293(8):2877-2887. doi: 10.1074/jbc.RA117.001342. Epub 2018 Jan 11.

7.

The Central Role of Amino Acids in Cancer Redox Homeostasis: Vulnerability Points of the Cancer Redox Code.

Vučetić M, Cormerais Y, Parks SK, Pouysségur J.

Front Oncol. 2017 Dec 21;7:319. doi: 10.3389/fonc.2017.00319. eCollection 2017. Review.

8.

Disrupting the 'Warburg effect' re-routes cancer cells to OXPHOS offering a vulnerability point via 'ferroptosis'-induced cell death.

Ždralević M, Vučetić M, Daher B, Marchiq I, Parks SK, Pouysségur J.

Adv Biol Regul. 2018 May;68:55-63. doi: 10.1016/j.jbior.2017.12.002. Epub 2017 Dec 28. Review.

9.

Disrupting glucose-6-phosphate isomerase fully suppresses the "Warburg effect" and activates OXPHOS with minimal impact on tumor growth except in hypoxia.

de Padua MC, Delodi G, Vučetić M, Durivault J, Vial V, Bayer P, Noleto GR, Mazure NM, Ždralević M, Pouysségur J.

Oncotarget. 2017 Sep 18;8(50):87623-87637. doi: 10.18632/oncotarget.21007. eCollection 2017 Oct 20.

10.

Dynamin inhibitors block activation of mTORC1 by amino acids independently of dynamin.

Persaud A, Cormerais Y, Pouyssegur J, Rotin D.

J Cell Sci. 2018 Jan 4;131(1). pii: jcs211755. doi: 10.1242/jcs.211755.

11.

Spontaneous chondroma formation in CD2-Cre-driven Erk-deficient mice.

Shiokawa M, Lu X, Miyake Y, Ishikawa E, Pagès G, Pouysségur J, Ogata M, Yamasaki S.

Int Immunol. 2017 Dec 18;29(10):479-485. doi: 10.1093/intimm/dxx056.

PMID:
29106539
12.

ERK1 is dispensable for mouse pancreatic beta cell function but is necessary for glucose-induced full activation of MSK1 and CREB.

Leduc M, Richard J, Costes S, Muller D, Varrault A, Compan V, Mathieu J, Tanti JF, Pagès G, Pouyssegur J, Bertrand G, Dalle S, Ravier MA.

Diabetologia. 2017 Oct;60(10):1999-2010. doi: 10.1007/s00125-017-4356-6. Epub 2017 Jul 18.

PMID:
28721437
13.

Extracellular Signal-Regulated Kinase Signaling in CD4-Expressing Cells Inhibits Osteochondromas.

Wehenkel M, Corr M, Guy CS, Edwards BA, Castellaw AH, Calabrese C, Pagès G, Pouysségur J, Vogel P, McGargill MA.

Front Immunol. 2017 May 1;8:482. doi: 10.3389/fimmu.2017.00482. eCollection 2017.

14.

Targeting pH regulating proteins for cancer therapy-Progress and limitations.

Parks SK, Pouysségur J.

Semin Cancer Biol. 2017 Apr;43:66-73. doi: 10.1016/j.semcancer.2017.01.007. Epub 2017 Jan 27. Review.

PMID:
28137473
15.

Hypoxia and cellular metabolism in tumour pathophysiology.

Parks SK, Cormerais Y, Pouysségur J.

J Physiol. 2017 Apr 15;595(8):2439-2450. doi: 10.1113/JP273309. Epub 2017 Feb 19. Review.

16.

Genetic disruption of the pHi-regulating proteins Na+/H+ exchanger 1 (SLC9A1) and carbonic anhydrase 9 severely reduces growth of colon cancer cells.

Parks SK, Cormerais Y, Durivault J, Pouyssegur J.

Oncotarget. 2017 Feb 7;8(6):10225-10237. doi: 10.18632/oncotarget.14379.

17.

Dissecting the Process of Activation of Cancer-promoting Zinc-requiring Ectoenzymes by Zinc Metalation Mediated by ZNT Transporters.

Tsuji T, Kurokawa Y, Chiche J, Pouysségur J, Sato H, Fukuzawa H, Nagao M, Kambe T.

J Biol Chem. 2017 Feb 10;292(6):2159-2173. doi: 10.1074/jbc.M116.763946. Epub 2016 Dec 27.

18.

Integration of a 'proton antenna' facilitates transport activity of the monocarboxylate transporter MCT4.

Noor SI, Pouyssegur J, Deitmer JW, Becker HM.

FEBS J. 2017 Jan;284(1):149-162. doi: 10.1111/febs.13964. Epub 2016 Dec 7.

19.

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M.

Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15.

20.

ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?

Buscà R, Pouysségur J, Lenormand P.

Front Cell Dev Biol. 2016 Jun 8;4:53. doi: 10.3389/fcell.2016.00053. eCollection 2016. Review.

21.

Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth.

Cormerais Y, Giuliano S, LeFloch R, Front B, Durivault J, Tambutté E, Massard PA, de la Ballina LR, Endou H, Wempe MF, Palacin M, Parks SK, Pouyssegur J.

Cancer Res. 2016 Aug 1;76(15):4481-92. doi: 10.1158/0008-5472.CAN-15-3376. Epub 2016 Jun 14. Erratum in: Cancer Res. 2017 Jul 1;77(13):3721.

22.

Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism.

Counillon L, Bouret Y, Marchiq I, Pouysségur J.

Biochim Biophys Acta. 2016 Oct;1863(10):2465-80. doi: 10.1016/j.bbamcr.2016.02.018. Epub 2016 Mar 2. Review.

23.

Hypoxia in health and disease.

Pouyssegur J, López-Barneo J.

Mol Aspects Med. 2016 Feb-Mar;47-48:1-2. doi: 10.1016/j.mam.2016.02.001. No abstract available.

PMID:
26857295
24.

Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export.

Parks SK, Cormerais Y, Marchiq I, Pouyssegur J.

Mol Aspects Med. 2016 Feb-Mar;47-48:3-14. doi: 10.1016/j.mam.2015.12.001. Epub 2015 Dec 23. Review.

PMID:
26724171
25.

ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1.

Buscà R, Christen R, Lovern M, Clifford AM, Yue JX, Goss GG, Pouysségur J, Lenormand P.

BMC Evol Biol. 2015 Sep 3;15:179. doi: 10.1186/s12862-015-0450-x.

26.

Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation.

Brahimi-Horn MC, Giuliano S, Saland E, Lacas-Gervais S, Sheiko T, Pelletier J, Bourget I, Bost F, Féral C, Boulter E, Tauc M, Ivan M, Garmy-Susini B, Popa A, Mari B, Sarry JE, Craigen WJ, Pouysségur J, Mazure NM.

Cancer Metab. 2015 Aug 26;3:8. doi: 10.1186/s40170-015-0133-5. eCollection 2015.

27.

Knock out of the BASIGIN/CD147 chaperone of lactate/H+ symporters disproves its pro-tumour action via extracellular matrix metalloproteases (MMPs) induction.

Marchiq I, Albrengues J, Granja S, Gaggioli C, Pouysségur J, Simon MP.

Oncotarget. 2015 Sep 22;6(28):24636-48. doi: 10.18632/oncotarget.4323.

28.

Monitoring Mitochondrial Pyruvate Carrier Activity in Real Time Using a BRET-Based Biosensor: Investigation of the Warburg Effect.

Compan V, Pierredon S, Vanderperre B, Krznar P, Marchiq I, Zamboni N, Pouyssegur J, Martinou JC.

Mol Cell. 2015 Aug 6;59(3):491-501. doi: 10.1016/j.molcel.2015.06.035.

29.

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters.

Marchiq I, Pouysségur J.

J Mol Med (Berl). 2016 Feb;94(2):155-71. doi: 10.1007/s00109-015-1307-x. Epub 2015 Jun 24. Review.

31.

Transient Blockade of ERK Phosphorylation in the Critical Period Causes Autistic Phenotypes as an Adult in Mice.

Yufune S, Satoh Y, Takamatsu I, Ohta H, Kobayashi Y, Takaenoki Y, Pagès G, Pouysségur J, Endo S, Kazama T.

Sci Rep. 2015 May 20;5:10252. doi: 10.1038/srep10252.

32.

Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status.

Granja S, Marchiq I, Le Floch R, Moura CS, Baltazar F, Pouysségur J.

Oncotarget. 2015 Mar 30;6(9):6708-21.

33.

Local mitochondrial-endolysosomal microfusion cleaves voltage-dependent anion channel 1 to promote survival in hypoxia.

Brahimi-Horn MC, Lacas-Gervais S, Adaixo R, Ilc K, Rouleau M, Notte A, Dieu M, Michiels C, Voeltzel T, Maguer-Satta V, Pelletier J, Ilie M, Hofman P, Manoury B, Schmidt A, Hiller S, Pouysségur J, Mazure NM.

Mol Cell Biol. 2015 May;35(9):1491-505. doi: 10.1128/MCB.01402-14. Epub 2015 Feb 17.

34.

The Na(+)/HCO3(-) Co-Transporter SLC4A4 Plays a Role in Growth and Migration of Colon and Breast Cancer Cells.

Parks SK, Pouyssegur J.

J Cell Physiol. 2015 Aug;230(8):1954-63. doi: 10.1002/jcp.24930.

PMID:
25612232
35.

Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin.

Marchiq I, Le Floch R, Roux D, Simon MP, Pouyssegur J.

Cancer Res. 2015 Jan 1;75(1):171-80. doi: 10.1158/0008-5472.CAN-14-2260. Epub 2014 Nov 17.

36.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D.

J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review.

PMID:
25347767
37.

Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.

Doyen J, Trastour C, Ettore F, Peyrottes I, Toussant N, Gal J, Ilc K, Roux D, Parks SK, Ferrero JM, Pouysségur J.

Biochem Biophys Res Commun. 2014 Aug 15;451(1):54-61. doi: 10.1016/j.bbrc.2014.07.050. Epub 2014 Jul 21.

PMID:
25058459
38.

Conventional techniques to monitor mitochondrial oxygen consumption.

Simonnet H, Vigneron A, Pouysségur J.

Methods Enzymol. 2014;542:151-61. doi: 10.1016/B978-0-12-416618-9.00008-X. Review.

PMID:
24862265
39.

Gene disruption using zinc finger nuclease technology.

Granja S, Marchiq I, Baltazar F, Pouysségur J.

Methods Mol Biol. 2014;1165:253-60. doi: 10.1007/978-1-4939-0856-1_17.

PMID:
24839030
40.

Biochemical titration of glycogen in vitro.

Pelletier J, Bellot G, Pouysségur J, Mazure NM.

J Vis Exp. 2013 Nov 24;(81):e50465. doi: 10.3791/50465.

41.

HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia.

HoWangYin KY, Loinard C, Bakker W, Guérin CL, Vilar J, d'Audigier C, Mauge L, Bruneval P, Emmerich J, Lévy BI, Pouysségur J, Smadja DM, Silvestre JS.

Stem Cells. 2014 Jan;32(1):231-43. doi: 10.1002/stem.1540. Erratum in: Stem Cells. 2014 Apr;32(4):1055-7. D'Audigier, Clément [corrected to d'Audigier, Clément].

42.

Disrupting proton dynamics and energy metabolism for cancer therapy.

Parks SK, Chiche J, Pouysségur J.

Nat Rev Cancer. 2013 Sep;13(9):611-23. doi: 10.1038/nrc3579. Review.

PMID:
23969692
43.

Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.

Ilie M, Hofman V, Zangari J, Chiche J, Mouroux J, Mazure NM, Pouysségur J, Brest P, Hofman P.

Lung Cancer. 2013 Oct;82(1):16-23. doi: 10.1016/j.lungcan.2013.07.005. Epub 2013 Jul 30.

PMID:
23910904
44.

Quantitative in vivo characterization of intracellular and extracellular pH profiles in heterogeneous tumors: a novel method enabling multiparametric pH analysis.

Lutz NW, Le Fur Y, Chiche J, Pouysségur J, Cozzone PJ.

Cancer Res. 2013 Aug 1;73(15):4616-28. doi: 10.1158/0008-5472.CAN-13-0767. Epub 2013 Jun 10. Erratum in: Cancer Res. 2013 Sep 15;73(18):5845.

45.

Tumor hypoxia and metabolism -- towards novel anticancer approaches.

Chiche J, Ricci JE, Pouysségur J.

Ann Endocrinol (Paris). 2013 May;74(2):111-4. doi: 10.1016/j.ando.2013.02.004. Epub 2013 Apr 15. Review.

PMID:
23597945
46.

MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines.

Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noël A, Pouysségur J, Barbry P, Mazure NM, Mari B.

Cell Death Dis. 2013 Mar 14;4:e544. doi: 10.1038/cddis.2013.71.

47.

Hypoxia promotes tumor cell survival in acidic conditions by preserving ATP levels.

Parks SK, Mazure NM, Counillon L, Pouysségur J.

J Cell Physiol. 2013 Sep;228(9):1854-62. doi: 10.1002/jcp.24346.

PMID:
23459996
48.

Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis.

Doyen J, Parks SK, Marcié S, Pouysségur J, Chiche J.

Front Oncol. 2013 Jan 7;2:199. doi: 10.3389/fonc.2012.00199. eCollection 2012.

49.

Mechanical allodynia but not thermal hyperalgesia is impaired in mice deficient for ERK2 in the central nervous system.

Otsubo Y, Satoh Y, Kodama M, Araki Y, Satomoto M, Sakamoto E, Pagès G, Pouysségur J, Endo S, Kazama T.

Pain. 2012 Nov;153(11):2241-52. doi: 10.1016/j.pain.2012.07.020. Epub 2012 Aug 16.

PMID:
22902213
50.

Polar opposites: Erk direction of CD4 T cell subsets.

Chang CF, D'Souza WN, Ch'en IL, Pages G, Pouyssegur J, Hedrick SM.

J Immunol. 2012 Jul 15;189(2):721-31. doi: 10.4049/jimmunol.1103015. Epub 2012 Jun 6.

Supplemental Content

Loading ...
Support Center